MINI FUTURE LONG - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 04:03:48 2024-07-01 EDT | ||
| 22.77 EUR / 22.97 EUR | -1.80% |
|
| Current month | +7.58% | ||
| 1 month | +11.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 23.29 | -0.94% |
| 24-06-27 | 23.51 | -0.08% |
| 24-06-26 | 23.53 | +0.90% |
| 24-06-25 | 23.32 | -0.98% |
| 24-06-24 | 23.55 | +1.64% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 03:21 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MD0SZT |
| ISIN | DE000MD0SZT9 |
| Date issued | 2021-12-27 |
| Strike | 223.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.26 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 24.4 € |
|---|---|
| Lowest since issue | 2.66 € |
| Spread | 0.2 € |
| Spread % | 0.87% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Certificates
- Certificat
